The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...

Our findings highlight the need for more research to understand the development of colon cancer in adults under age 45,” one ...

In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...

In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

Recent clinical research from BGI Genomics and Zhongshan Hospital, Fudan University, highlights the effectiveness of ...

After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer ...

Tammy Morrow, 55, had been healthy for decades when, after seeing a doctor for what she thought was a stomach ... to cancer treatment that personalizes chemotherapy based on a patient’s genetic ...

The IHC companion diagnostic test determines CLDN18 protein expression and may help identify patients who are eligible for treatment with Vyloy.

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with ...